Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 10/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806024 | 0.82 | CHRNB4 (0.57) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL24310074 | 0.81 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNA7MAOB | |
| SCHEMBL18985115 | 0.80 | CHRNB4 (0.67) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL165812 | 0.78 | CHRNB4 (0.87) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL2809629 | 0.75 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL2879014 | 0.74 | LTA4H (0.63) | ALDH1A1GAAMAOBLTA4HTSHR | |
| SCHEMBL14894412 | 0.74 | MAOB (0.47) | ALDH1A1GAAMAOBLTA4HTSHR | |
| SCHEMBL895500 | 0.73 | CHRNB4 (1.00) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL433117 | 0.73 | CHRNB4 (0.90) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 | |
| SCHEMBL20819791 | 0.73 | CHRNB4 (0.53) | CHRNB4CHRNA3CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| EP-2253614-B1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-1735307-B1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | CHRNB4 3843/4885CHRNA3 4283/4885CHRNA7 4152/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | CHRNB4 4516/4885CHRNA3 4655/4885CHRNA7 4619/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | CHRNB4 3951/4885CHRNA3 4416/4885CHRNA7 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.